VIA PHARMACEUTICALS INC( VIAP :NASDAQ) - 500 Beiträge pro Seite
eröffnet am 02.05.09 10:09:08 von
neuester Beitrag 12.11.09 10:21:51 von
neuester Beitrag 12.11.09 10:21:51 von
Beiträge: 9
ID: 1.150.066
ID: 1.150.066
Aufrufe heute: 0
Gesamt: 1.982
Gesamt: 1.982
Aktive User: 0
ISIN: US92554T1034 · WKN: A0MUJE · Symbol: VIAP
0,0000
USD
0,00 %
0,0000 USD
Letzter Kurs 08.03.24 Nasdaq OTC
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 0,5400 | +38,46 | |
| 1,9900 | +32,67 | |
| 5,4000 | +27,06 | |
| 1,8250 | +25,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 14,510 | -32,32 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 | |
| 1,7700 | -46,69 | |
| 84,75 | -74,50 |
Feedback
VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
Data Presented at American Heart Association ATVB Conference Shows Reduction in Non-Calcified Plaque Volume and Fewer New Plaque Lesions in Treated Patients
Related Quotes
WASHINGTON and SAN FRANCISCO, May 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP - News) today announced the results of a sub-study of patients in its acute coronary syndrome (ACS) Phase 2 trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of treatment with its lead drug, VIA-2291, an inhibitor of leukotrienes, proposed mediators of vascular inflammation. Results were presented in a poster session at the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference 2009 in Washington, D.C. by Jean-Claude Tardif MD, of the Montreal Heart Institute, and Dr. Rebecca Taub, VIA's Senior Vice President - Research & Development.
Of 191 patients enrolled in the first 12 weeks of the ACS trial, over 85 elected to continue in the study for an additional 12 weeks, receiving either placebo or VIA-2291 on top of current standard medical care. Each of these patients received an MDCT scan at baseline and at 24 weeks. Evaluable scans from patients treated with placebo showed significantly more evidence of new plaque lesions at follow-up than VIA-2291 treated patients. MDCT scans of patients with low density plaques demonstrated statistically significant, lower plaque volumes in combined VIA treated groups compared to placebo. Together these results suggest that VIA-2291 may reduce the progression of unstable coronary plaques that lead to heart attacks and stroke.
Despite advances in treatment, cardiovascular disease remains a leading cause of death and disability in the United States and the world. Emerging research points to the potential for inflammation within the vascular wall to be a key contributing factor in major adverse cardiac events (MACE) such as heart attack or stroke. This ACS sub-study is the first clinical trial to use MDCT imaging to assess the effects of a drug on coronary plaque in a large patient cohort. MDCT is a state-of-the-art imaging technology that enables non-invasive imaging of coronary vessels.
"This innovative imaging technology has, for the first time, allowed us to visually and non-invasively demonstrate a reduction in plaque volume and a reduced number of new plaque lesions," said Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute Research Centre, professor of medicine at the University of Montreal and principal investigator of the VIA-2291 ACS trial. "In the ACS study results presented in 2008, we discussed VIA-2291's ability to reduce high sensitivity C-reactive protein (hs-CRP), a biomarker for inflammation. Taken as a whole, these results are an important step forward in understanding the importance of one cardiovascular inflammatory pathway."
"VIA-2291 continues to show a significant effect on vascular inflammation, and these data add to the weight of the evidence from our Phase 2 trial program," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA. "We have now combined histology, non-invasive imaging and biomarker data to demonstrate the impact of VIA-2291. This adds support to our clinical development efforts and gives us even greater confidence as we look to move into in a larger trial."
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.
Data Presented at American Heart Association ATVB Conference Shows Reduction in Non-Calcified Plaque Volume and Fewer New Plaque Lesions in Treated Patients
Related Quotes
WASHINGTON and SAN FRANCISCO, May 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP - News) today announced the results of a sub-study of patients in its acute coronary syndrome (ACS) Phase 2 trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of treatment with its lead drug, VIA-2291, an inhibitor of leukotrienes, proposed mediators of vascular inflammation. Results were presented in a poster session at the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference 2009 in Washington, D.C. by Jean-Claude Tardif MD, of the Montreal Heart Institute, and Dr. Rebecca Taub, VIA's Senior Vice President - Research & Development.
Of 191 patients enrolled in the first 12 weeks of the ACS trial, over 85 elected to continue in the study for an additional 12 weeks, receiving either placebo or VIA-2291 on top of current standard medical care. Each of these patients received an MDCT scan at baseline and at 24 weeks. Evaluable scans from patients treated with placebo showed significantly more evidence of new plaque lesions at follow-up than VIA-2291 treated patients. MDCT scans of patients with low density plaques demonstrated statistically significant, lower plaque volumes in combined VIA treated groups compared to placebo. Together these results suggest that VIA-2291 may reduce the progression of unstable coronary plaques that lead to heart attacks and stroke.
Despite advances in treatment, cardiovascular disease remains a leading cause of death and disability in the United States and the world. Emerging research points to the potential for inflammation within the vascular wall to be a key contributing factor in major adverse cardiac events (MACE) such as heart attack or stroke. This ACS sub-study is the first clinical trial to use MDCT imaging to assess the effects of a drug on coronary plaque in a large patient cohort. MDCT is a state-of-the-art imaging technology that enables non-invasive imaging of coronary vessels.
"This innovative imaging technology has, for the first time, allowed us to visually and non-invasively demonstrate a reduction in plaque volume and a reduced number of new plaque lesions," said Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute Research Centre, professor of medicine at the University of Montreal and principal investigator of the VIA-2291 ACS trial. "In the ACS study results presented in 2008, we discussed VIA-2291's ability to reduce high sensitivity C-reactive protein (hs-CRP), a biomarker for inflammation. Taken as a whole, these results are an important step forward in understanding the importance of one cardiovascular inflammatory pathway."
"VIA-2291 continues to show a significant effect on vascular inflammation, and these data add to the weight of the evidence from our Phase 2 trial program," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA. "We have now combined histology, non-invasive imaging and biomarker data to demonstrate the impact of VIA-2291. This adds support to our clinical development efforts and gives us even greater confidence as we look to move into in a larger trial."
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.
VIA Pharmaceuticals, Inc. ist ein Biotechnologie Unternehmen, das sich auf die Entwicklung von Verbindungen zur Behandlung von Herz-Kreislauf-und Stoffwechselkrankheiten. VIA's Kandidaten führen, VIA-2291, zielt auf eine erhebliche medizinischen Bedarf: Verringerung der Entzündung in der Wand der Blutgefäße, was eine Ursache der Atherosklerose und ihre Komplikationen, darunter Herzinfarkt und Schlaganfall. Darüber hinaus, VIA's Pipeline von Wirkstoffkandidaten weitere Verbindungen zu anderen zugrunde liegenden Ursachen von Herz-Kreislauf-Erkrankungen: ein hoher Cholesterinspiegel, Diabetes und Entzündungen. Für weitere Informationen, besuchen Sie: http://www.viapharmaceuticals.com.
heute ging hier die Post ab. Zwischendurch 23% und zum Schluss immer noch fast 10%
Da kommt was! Da hat wer mehr gewußt - oder gepennt und Limit vergessen
Da kommt was! Da hat wer mehr gewußt - oder gepennt und Limit vergessen
Trading Spotlight
jetzt schon über 20% im Plus. Also da kommt wirklich was. Und der Umsatz ist auch anständig.
Endlich bin ich auch mal knapp rechtzeitig eingestiegen
Endlich bin ich auch mal knapp rechtzeitig eingestiegen
der Kurs ist derzeit festgenagelt, die nächsten Meldungen müssten nun auch bald mal kommen.
VIA Pharmaceuticals gibt am 10. November die Ergebnisse der Phase 2 für das Präparat VIA-2291. Es soll gegen Arteriosklerose eingesetzt werden.
Sollte die Phase 2 erfolgreich abgeschlossen werden, wird sich das natürlich im Aktienkurs bemerkbar machen. Derzeit bei 0,38 USD/Aktie, ist das Papier dann möglicherweise unterbewertet.
Sollte die Phase 2 erfolgreich abgeschlossen werden, wird sich das natürlich im Aktienkurs bemerkbar machen. Derzeit bei 0,38 USD/Aktie, ist das Papier dann möglicherweise unterbewertet.
Antwort auf Beitrag Nr.: 38.341.613 von truthwatch am 07.11.09 19:23:52November 17, 2009 at the American Heart Association Scientific Sessions 2009 in Orlando, Florida
hier sollen Details zur Phase II Studie bekannt gegeben werden. Das erklärt aber nicht den Rutsch des Kurses
hier sollen Details zur Phase II Studie bekannt gegeben werden. Das erklärt aber nicht den Rutsch des Kurses
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,35 | |
| +0,05 | |
| - | |
| -0,59 | |
| 0,00 | |
| +2,47 | |
| -2,34 | |
| -0,02 | |
| +0,04 | |
| -99,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 196 | ||
| 93 | ||
| 66 | ||
| 50 | ||
| 46 | ||
| 43 | ||
| 42 | ||
| 37 | ||
| 33 | ||
| 27 |
